28 completed, 7 unknown, 5 not yet recruiting, 3 withdrawn. 35 Phase 1, 3 Phase 4, 2 Not applicable, 2 Phase 2, 2 Phase 3.
Follow Test Drug: new trials by email Literature Review of Test Drug trials Research Report on Test Drug
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 61 | 2026-08-06 | 2026-09-09 |
| Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 36 | 2026-07-01 | 2026-06-11 |
| Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions Test Drug, Reference Drug - Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | Phase 1 | Completed | AJU Pharm Co., Ltd. | 45 | 2026-06-27 | 2026-09-21 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer CKD-215, D215 - Ovarian Cancer | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 24 | 2026-06-01 | 2026-04-15 |
| A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults Comparator 1, Comparator 2, Test Drug - Type2 Diabetes Mellitus | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 50 | 2025-08-01 | 2025-06-24 |
| A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study Comparator 1, Comparator 2, Test Drug - Type2 Diabetes Mellitus | Phase 1 | Not yet recruiting | AJU Pharm Co., Ltd. | 32 | 2025-08-01 | 2025-07-01 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults Test Drug, Reference Drug - Dyslipidemia | Phase 1 | Active not recruiting | AJU Pharm Co., Ltd. | 60 | 2025-05-24 | 2025-06-12 |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A AD-120A, AD-120 - Gastroesophageal Reflux Disease (GERD) | Phase 1 | Not yet recruiting | Addpharma Inc. | 48 | 2025-04-21 | 2025-04-08 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 60 | 2025-03-29 | 2025-06-12 |
| A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability Test Drug (Eutropin Catridge, 48IU/Cartridge), Reference Drug (Eutropin, 4 IU/vial) - Healthy Volunteers | Phase 1 | Completed | LG Chem | 48 | 2025-01-13 | 2025-04-17 |
| Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics Vamorolone, Midazolam - Drug Interaction | Phase 1 | Completed | Santhera Pharmaceuticals | 18 | 2024-08-13 | 2025-12-15 |
| Bioequivalence Study of Rosuvastatin Tablet Test Drug, Reference Drug - Healthy Individuals | Not applicable | Completed | University of Karachi | 36 | 2022-11-24 | 2023-03-22 |
| A Phase 1 Study of EXT608 in Healthy Adults EXT608, Placebo - Safety Issues | Phase 1 | Completed | Extend Biosciences Inc. | 24 | 2022-07-21 | 2025-02-04 |
| Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model IP2015, dose 1, IP2015, dose 2, Placebo - Pain | Phase 1 | Unknown | Initiator Pharma | 24 | 2022-01-05 | 2022-01-06 |
| A Study to Compare PK, PD and Safety of the AD-214 and AD-2141 AD-214, AD-2141 - Gastroesophageal Reflux Disease | Phase 1 | Completed | Addpharma Inc. | 41 | 2021-11-01 | 2022-07-20 |
| Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis X0002 Spray, Celecoxib capsules, placebo - KNEE OSTEOARTHRITIS | Phase 3 | Completed | Jiangsu XinChen-Techfields Pharma Co., LTD. | 180 | 2021-09-29 | 2023-03-07 |
| A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers C52R1H Tab. and C52R2 Tab., AJU-C52L - Hypertension | Phase 1 | Unknown | AJU Pharm Co., Ltd. | 60 | 2021-09-24 | 2021-10-14 |
| A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers C52R1M Tab. and C52R2 Tab., AJU-C52H - Hypertension | Phase 1 | Unknown | AJU Pharm Co., Ltd. | 60 | 2021-09-17 | 2021-10-14 |
| A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers Lixiana(D006), CKD-344 - Anticoagulant | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 60 | 2021-04-27 | 2021-04-30 |
Showing 20 of 44. Sign in to see all of them.
Dyslipidemias (4) · Gastroesophageal Reflux (3) · Hypertension (3) · Cardiovascular Diseases (2) · Diabetes Mellitus, Type 2 (2) · Hypercholesterolemia (2) · Osteoarthritis, Knee (2) · Pain (2) · Diabetic Neuropathies (1) · Gastritis (1) · Heroin Dependence (1) · Hyperlipidemias (1) · Hypogonadism (1) · Neuralgia (1) · Neuralgia, Postherpetic (1)
AJU Pharm Co., Ltd. (11) · Chong Kun Dang Pharmaceutical (9) · Pfizer (5) · Addpharma Inc. (4) · Atabay Kimya Sanayi Ticaret A.S. (1) · Avilex Pharma (1) · Boehringer Ingelheim (1) · Brigham and Women's Hospital (1) · Extend Biosciences Inc. (1) · GL Pharm Tech Corporation (1) · Geropharm (1) · Initiator Pharma (1) · Jiangsu XinChen-Techfields Pharma Co., LTD. (1) · LG Chem (1) · Laboratorios Andromaco S.A. (1)
South Korea (27) · United States (3) · Brazil (2) · China (2) · Chile (1) · Finland (1) · Germany (1) · Pakistan (1) · Russia (1) · Turkey (Türkiye) (1)
Min-gul Kim (3) · Seunghwan Lee, M.D.,Ph.D (2) · Yook-Hwan Noh (2) · An-Hye Kim, M.D., PhD. (1) · Hyewon Chung, M.D., PhD. (1) · In-Jin Jang, M.D.,Ph.D (1) · Jang Hee Hong (1) · Jeong-Yeol Park, Ph.D (1) · Laura Hales, PhD (1) · Leslie Amass, Ph.D. (1) · Michael Lissy, MD (1) · Mika Scheinin, MD (1) · Min-Gul Kim, Ph.D. (1)
R01DA011160 (1), R44DK107231 (1)